Quest Diagnostics (DGX) Earnings Date & Reports

Key Takeaways

• Quest Diagnostics reported third-quarter 2026 revenue of $3.1 billion, up 10% year over year, exceeding Wall Street estimates.
• Adjusted earnings per share (EPS) came in at $3.00, up 15.4% from $2.60 a year earlier and ahead of consensus expectations.
• Total testing volume, measured by requisitions, rose 14.5% year over year, with organic volume up 14.4%.
• Management raised and narrowed its full-year 2026 guidance for both revenue and EPS, citing sustained demand across physician, hospital, and consumer channels.
• Despite the beat and raised outlook, shares traded modestly lower in early trading following the release.

Earnings Context and Why It Matters

Quest Diagnostics is one of the largest providers of diagnostic information services in the United States, processing roughly one-third of the adult population's lab tests each year. Its quarterly results are closely watched as a barometer of overall healthcare utilization and consumer health trends. Heading into the report, investors were focused on whether strong testing demand could offset pressure on pricing and reimbursement, particularly as the company integrates its Corewell Health and Fresenius Medical Care partnerships. The third-quarter update carried added weight because it signaled whether Quest's growth momentum and margin trajectory could support another increase to its annual outlook.

Reported Results

For the three months ended September 30, 2026, Quest Diagnostics reported consolidated revenue of $3.1 billion, a 10% increase from the prior-year quarter. Diagnostic Information Services revenue grew 10.2% year over year, including 10.1% organic growth. The results exceeded the Zacks Consensus Estimate for revenue by roughly 1.7%.

Reported (GAAP) EPS was $2.78, up from $2.16 in the year-ago period. On an adjusted basis, EPS was $3.00, a 15.4% increase from $2.60 a year earlier and above the consensus estimate of $2.85, representing a beat of more than 5%.

Total testing volume climbed 14.5% year over year, with organic volume up 14.4%. The Corewell Health and Fresenius Medical Care relationships contributed 9.5% of volume in the quarter. Revenue per requisition declined 4.2% due to that business mix, but rose 1.7% after adjusting for it. Reported operating income was $479 million, or 15.5% of revenue, compared with $386 million, or 13.7%, a year earlier. Adjusted operating income reached $517 million, or 16.7% of revenue, a 40-basis-point margin improvement.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Quest Diagnostics, it offers a structured way to surface opportunities across the healthcare and diagnostics landscape.

Market Reaction and Investor Sentiment

Despite a solid earnings and revenue beat, plus raised guidance, Quest Diagnostics shares edged lower in pre-market and early trading following the announcement. That reaction suggests investors had largely priced in the company's momentum and may have been looking for an even stronger forward signal. Sentiment around the stock remains broadly constructive, supported by sustained demand across testing channels and productivity gains from automation and artificial intelligence. However, concerns about reimbursement pressures and the revenue-per-requisition decline tied to new partnerships tempered enthusiasm.

Forward Outlook and Key Factors to Monitor

Quest Diagnostics raised and narrowed its full-year 2026 guidance following the third quarter. The company now expects revenue between $12.065 billion and $12.105 billion, representing growth of 9.3% to 9.7%, and adjusted EPS in a range of $11.25 to $11.35. Cash from operations is projected at approximately $1.9 billion, with capital expenditures of roughly $550 million.

Looking further ahead, investors should watch the company's commentary on reimbursement changes. Management estimates that PAMA (the Protecting Access to Medicare Act) rate-setting framework could reduce 2027 revenue by about 1%, with a cumulative impact of less than 1.3% from 2027 through 2029. Quest continues to advocate for the RESULTS Act to reform PAMA data collection.

Other factors to monitor include the continued ramp of the Corewell Health and Fresenius Medical Care collaborations, the growth trajectory of the consumer health segment, and progress on the Project Nova technology initiative. Cost trends, including wage inflation and fuel expenses, will also remain relevant to margin expansion. Quest plans to provide full 2027 guidance alongside its fourth-quarter results and will host its Investor Day on March 25, 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations